Apellis Pharmaceuticals
Platform of novel therapeutic compounds for the treatment of autoimmune diseases.
Launch date
Employees
Market cap
€4.2b
Enterprise valuation
€4.3b (Public information from Sep 2024)
Share price
$35.63 APLS
Waltham Massachusetts (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 251m | 66.6m | 75.4m | 397m | 796m | 1.0b | 1.5b |
| % growth | - | (73 %) | 13 % | 426 % | 101 % | 32 % | 39 % |
| EBITDA | (209m) | (533m) | (584m) | (495m) | (97.3m) | 163m | 528m |
| % EBITDA margin | (84 %) | (801 %) | (775 %) | (125 %) | (12 %) | 16 % | 36 % |
| Profit | (345m) | (746m) | (652m) | (529m) | (157m) | 22.0m | 294m |
| % profit margin | (138 %) | (1121 %) | (865 %) | (133 %) | (20 %) | 2 % | 20 % |
| EV / revenue | 15.0x | 62.7x | 69.7x | 17.2x | 6.0x | 4.2x | 2.4x |
| EV / EBITDA | -18.0x | -7.8x | -9.0x | -13.8x | -48.7x | 27.1x | 6.5x |
| R&D budget | 300m | 421m | 387m | 354m | - | - | - |
| R&D % of revenue | 120 % | 632 % | 513 % | 89 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$1.7m | Early VC | ||
$3.0m | Series A | ||
N/A | Series B | ||
$6.0m | Early VC | ||
| N/A | $17.8m | Late VC | |
$33.0m | Series C | ||
$47.0m | Series D | ||
* | $60.0m | Series E | |
| N/A | N/A | IPO | |
N/A | Post IPO Equity | ||
* | N/A | $403m | Post IPO Equity |
* | $475m | Post IPO Debt | |
| Total Funding | €153m | ||
Related Content
Recent News about Apellis Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.